nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—CYP3A4—Temozolomide—malignant glioma	0.246	1	CbGbCtD
Rivaroxaban—Hemiparesis—Temozolomide—malignant glioma	0.0263	0.104	CcSEcCtD
Rivaroxaban—Haemorrhage intracranial—Temozolomide—malignant glioma	0.0134	0.0531	CcSEcCtD
Rivaroxaban—Cerebral haemorrhage—Carmustine—malignant glioma	0.0103	0.0407	CcSEcCtD
Rivaroxaban—Cerebral haemorrhage—Temozolomide—malignant glioma	0.00995	0.0394	CcSEcCtD
Rivaroxaban—Menorrhagia—Temozolomide—malignant glioma	0.00744	0.0294	CcSEcCtD
Rivaroxaban—Cholestasis—Temozolomide—malignant glioma	0.00726	0.0287	CcSEcCtD
Rivaroxaban—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.0067	0.0265	CcSEcCtD
Rivaroxaban—Swelling—Carmustine—malignant glioma	0.00469	0.0186	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.00414	0.0164	CcSEcCtD
Rivaroxaban—Renal failure—Carmustine—malignant glioma	0.00314	0.0124	CcSEcCtD
Rivaroxaban—Urinary tract infection—Carmustine—malignant glioma	0.0031	0.0123	CcSEcCtD
Rivaroxaban—Infestation—Temozolomide—malignant glioma	0.00308	0.0122	CcSEcCtD
Rivaroxaban—Infestation NOS—Temozolomide—malignant glioma	0.00308	0.0122	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.00306	0.0121	CcSEcCtD
Rivaroxaban—Urinary tract infection—Temozolomide—malignant glioma	0.003	0.0119	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Temozolomide—malignant glioma	0.00292	0.0115	CcSEcCtD
Rivaroxaban—Sinusitis—Temozolomide—malignant glioma	0.00289	0.0114	CcSEcCtD
Rivaroxaban—Haemoglobin—Carmustine—malignant glioma	0.00288	0.0114	CcSEcCtD
Rivaroxaban—Haemorrhage—Carmustine—malignant glioma	0.00286	0.0113	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Carmustine—malignant glioma	0.00281	0.0111	CcSEcCtD
Rivaroxaban—Haemoglobin—Temozolomide—malignant glioma	0.00278	0.011	CcSEcCtD
Rivaroxaban—Haemorrhage—Temozolomide—malignant glioma	0.00277	0.0109	CcSEcCtD
Rivaroxaban—Hepatitis—Temozolomide—malignant glioma	0.00277	0.0109	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Temozolomide—malignant glioma	0.00273	0.0108	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Temozolomide—malignant glioma	0.00272	0.0108	CcSEcCtD
Rivaroxaban—Urethral disorder—Temozolomide—malignant glioma	0.00271	0.0107	CcSEcCtD
Rivaroxaban—Eye disorder—Carmustine—malignant glioma	0.00268	0.0106	CcSEcCtD
Rivaroxaban—Erythema multiforme—Temozolomide—malignant glioma	0.00262	0.0103	CcSEcCtD
Rivaroxaban—Eye disorder—Temozolomide—malignant glioma	0.00259	0.0102	CcSEcCtD
Rivaroxaban—Cardiac disorder—Temozolomide—malignant glioma	0.00257	0.0102	CcSEcCtD
Rivaroxaban—Angiopathy—Temozolomide—malignant glioma	0.00251	0.00993	CcSEcCtD
Rivaroxaban—Immune system disorder—Temozolomide—malignant glioma	0.0025	0.00989	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Temozolomide—malignant glioma	0.00249	0.00986	CcSEcCtD
Rivaroxaban—Back pain—Carmustine—malignant glioma	0.00241	0.00954	CcSEcCtD
Rivaroxaban—Back pain—Temozolomide—malignant glioma	0.00233	0.00922	CcSEcCtD
Rivaroxaban—Anaemia—Carmustine—malignant glioma	0.0023	0.00911	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Temozolomide—malignant glioma	0.00224	0.00884	CcSEcCtD
Rivaroxaban—Anaemia—Temozolomide—malignant glioma	0.00223	0.00881	CcSEcCtD
Rivaroxaban—Angioedema—Temozolomide—malignant glioma	0.0022	0.00871	CcSEcCtD
Rivaroxaban—Malaise—Temozolomide—malignant glioma	0.00217	0.00859	CcSEcCtD
Rivaroxaban—Chest pain—Carmustine—malignant glioma	0.00212	0.00839	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00204	0.00806	CcSEcCtD
Rivaroxaban—Oedema—Carmustine—malignant glioma	0.00203	0.00805	CcSEcCtD
Rivaroxaban—Discomfort—Temozolomide—malignant glioma	0.00203	0.00801	CcSEcCtD
Rivaroxaban—Infection—Carmustine—malignant glioma	0.00202	0.00799	CcSEcCtD
Rivaroxaban—Dry mouth—Temozolomide—malignant glioma	0.00201	0.00793	CcSEcCtD
Rivaroxaban—Tachycardia—Carmustine—malignant glioma	0.00199	0.00785	CcSEcCtD
Rivaroxaban—CYP2J2—Biological oxidations—PTGS1—malignant glioma	0.00197	0.00398	CbGpPWpGaD
Rivaroxaban—Anaphylactic shock—Temozolomide—malignant glioma	0.00197	0.00778	CcSEcCtD
Rivaroxaban—Oedema—Temozolomide—malignant glioma	0.00197	0.00778	CcSEcCtD
Rivaroxaban—Infection—Temozolomide—malignant glioma	0.00195	0.00772	CcSEcCtD
Rivaroxaban—CYP3A4—Xenobiotics—CYP2C18—malignant glioma	0.00195	0.00394	CbGpPWpGaD
Rivaroxaban—Nervous system disorder—Temozolomide—malignant glioma	0.00193	0.00763	CcSEcCtD
Rivaroxaban—Skin disorder—Temozolomide—malignant glioma	0.00191	0.00755	CcSEcCtD
Rivaroxaban—Hypotension—Carmustine—malignant glioma	0.0019	0.00752	CcSEcCtD
Rivaroxaban—CYP3A4—Irinotecan Pathway—BCHE—malignant glioma	0.00183	0.00369	CbGpPWpGaD
Rivaroxaban—Dyspnoea—Carmustine—malignant glioma	0.00181	0.00717	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Carmustine—malignant glioma	0.00176	0.00695	CcSEcCtD
Rivaroxaban—Dyspnoea—Temozolomide—malignant glioma	0.00175	0.00693	CcSEcCtD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2C18—malignant glioma	0.00174	0.00352	CbGpPWpGaD
Rivaroxaban—Pain—Carmustine—malignant glioma	0.00174	0.00688	CcSEcCtD
Rivaroxaban—Constipation—Carmustine—malignant glioma	0.00174	0.00688	CcSEcCtD
Rivaroxaban—Dyspepsia—Temozolomide—malignant glioma	0.00173	0.00684	CcSEcCtD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP2C18—malignant glioma	0.00172	0.00347	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—ATP1B2—malignant glioma	0.0017	0.00343	CbGpPWpGaD
Rivaroxaban—Gastrointestinal disorder—Temozolomide—malignant glioma	0.0017	0.00671	CcSEcCtD
Rivaroxaban—Fatigue—Temozolomide—malignant glioma	0.00169	0.0067	CcSEcCtD
Rivaroxaban—Constipation—Temozolomide—malignant glioma	0.00168	0.00665	CcSEcCtD
Rivaroxaban—Pain—Temozolomide—malignant glioma	0.00168	0.00665	CcSEcCtD
Rivaroxaban—Feeling abnormal—Carmustine—malignant glioma	0.00168	0.00663	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Carmustine—malignant glioma	0.00166	0.00658	CcSEcCtD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP2B6—malignant glioma	0.00163	0.00329	CbGpPWpGaD
Rivaroxaban—CYP3A4—Tryptophan metabolism—ASMT—malignant glioma	0.00162	0.00327	CbGpPWpGaD
Rivaroxaban—Feeling abnormal—Temozolomide—malignant glioma	0.00162	0.00641	CcSEcCtD
Rivaroxaban—Abdominal pain—Carmustine—malignant glioma	0.00161	0.00636	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Temozolomide—malignant glioma	0.00161	0.00636	CcSEcCtD
Rivaroxaban—Urticaria—Temozolomide—malignant glioma	0.00156	0.00618	CcSEcCtD
Rivaroxaban—Abdominal pain—Temozolomide—malignant glioma	0.00155	0.00615	CcSEcCtD
Rivaroxaban—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2B6—malignant glioma	0.00155	0.00312	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Carmustine—malignant glioma	0.0015	0.00593	CcSEcCtD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—NDRG1—malignant glioma	0.0015	0.00302	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—RTEL1—malignant glioma	0.00148	0.00298	CbGpPWpGaD
Rivaroxaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2B6—malignant glioma	0.00147	0.00297	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—GSTP1—malignant glioma	0.00146	0.00295	CbGpPWpGaD
Rivaroxaban—Asthenia—Carmustine—malignant glioma	0.00146	0.00577	CcSEcCtD
Rivaroxaban—Hypersensitivity—Temozolomide—malignant glioma	0.00145	0.00573	CcSEcCtD
Rivaroxaban—CYP2J2—Metapathway biotransformation—GSTP1—malignant glioma	0.00144	0.00291	CbGpPWpGaD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP2C18—malignant glioma	0.00141	0.00285	CbGpPWpGaD
Rivaroxaban—Asthenia—Temozolomide—malignant glioma	0.00141	0.00558	CcSEcCtD
Rivaroxaban—Diarrhoea—Carmustine—malignant glioma	0.00139	0.00551	CcSEcCtD
Rivaroxaban—Pruritus—Temozolomide—malignant glioma	0.00139	0.0055	CcSEcCtD
Rivaroxaban—CYP2J2—blood vessel—malignant glioma	0.00138	0.237	CbGeAlD
Rivaroxaban—Dizziness—Carmustine—malignant glioma	0.00135	0.00532	CcSEcCtD
Rivaroxaban—Diarrhoea—Temozolomide—malignant glioma	0.00135	0.00532	CcSEcCtD
Rivaroxaban—Dizziness—Temozolomide—malignant glioma	0.0013	0.00514	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—GDNF—malignant glioma	0.00129	0.00261	CbGpPWpGaD
Rivaroxaban—Vomiting—Carmustine—malignant glioma	0.00129	0.00512	CcSEcCtD
Rivaroxaban—Rash—Carmustine—malignant glioma	0.00128	0.00507	CcSEcCtD
Rivaroxaban—Dermatitis—Carmustine—malignant glioma	0.00128	0.00507	CcSEcCtD
Rivaroxaban—Headache—Carmustine—malignant glioma	0.00127	0.00504	CcSEcCtD
Rivaroxaban—F10—Hemostasis—ANGPT2—malignant glioma	0.00125	0.00253	CbGpPWpGaD
Rivaroxaban—Vomiting—Temozolomide—malignant glioma	0.00125	0.00494	CcSEcCtD
Rivaroxaban—Rash—Temozolomide—malignant glioma	0.00124	0.0049	CcSEcCtD
Rivaroxaban—Dermatitis—Temozolomide—malignant glioma	0.00124	0.0049	CcSEcCtD
Rivaroxaban—Headache—Temozolomide—malignant glioma	0.00123	0.00487	CcSEcCtD
Rivaroxaban—Nausea—Carmustine—malignant glioma	0.00121	0.00478	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—XBP1—malignant glioma	0.00121	0.00244	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IL12A—malignant glioma	0.00118	0.00239	CbGpPWpGaD
Rivaroxaban—Nausea—Temozolomide—malignant glioma	0.00117	0.00462	CcSEcCtD
Rivaroxaban—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—malignant glioma	0.00111	0.00225	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—HIST1H3B—malignant glioma	0.00108	0.00219	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—MYB—malignant glioma	0.00107	0.00217	CbGpPWpGaD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	0.00107	0.00216	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—IDH1—malignant glioma	0.00105	0.00213	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—SPHK1—malignant glioma	0.00102	0.00206	CbGpPWpGaD
Rivaroxaban—CYP3A4—Tryptophan metabolism—CYP2C18—malignant glioma	0.001	0.00202	CbGpPWpGaD
Rivaroxaban—CYP3A4—Irinotecan Pathway—APC—malignant glioma	0.000993	0.002	CbGpPWpGaD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2B6—malignant glioma	0.000935	0.00189	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—TFRC—malignant glioma	0.000924	0.00186	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP2B6—malignant glioma	0.000922	0.00186	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—SPHK1—malignant glioma	0.000896	0.00181	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-C—malignant glioma	0.000875	0.00177	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—CYP2B6—malignant glioma	0.000866	0.00175	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP2B6—malignant glioma	0.000854	0.00172	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—COX8A—malignant glioma	0.000848	0.00171	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—H3F3A—malignant glioma	0.000837	0.00169	CbGpPWpGaD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C18—malignant glioma	0.00081	0.00164	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP2C18—malignant glioma	0.0008	0.00161	CbGpPWpGaD
Rivaroxaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—malignant glioma	0.000765	0.00154	CbGpPWpGaD
Rivaroxaban—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—malignant glioma	0.000763	0.00154	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTGS1—malignant glioma	0.000758	0.00153	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP2B6—malignant glioma	0.000758	0.00153	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—CYP2C18—malignant glioma	0.000751	0.00152	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IL12B—malignant glioma	0.000744	0.0015	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP2C18—malignant glioma	0.00074	0.00149	CbGpPWpGaD
Rivaroxaban—F10—Post-translational protein modification—F2—malignant glioma	0.000739	0.00149	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—ASMT—malignant glioma	0.000721	0.00146	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—BCHE—malignant glioma	0.000705	0.00142	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—KNG1—malignant glioma	0.00069	0.00139	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—BCAN—malignant glioma	0.000678	0.00137	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—IFNA2—malignant glioma	0.000676	0.00136	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—STMN1—malignant glioma	0.000674	0.00136	CbGpPWpGaD
Rivaroxaban—CYP2J2—telencephalon—malignant glioma	0.000668	0.115	CbGeAlD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C18—malignant glioma	0.000657	0.00133	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—SOD1—malignant glioma	0.000641	0.00129	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—BCHE—malignant glioma	0.000618	0.00125	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—FBXW7—malignant glioma	0.000608	0.00123	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—GSTT1—malignant glioma	0.000607	0.00123	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—PTK2—malignant glioma	0.000589	0.00119	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—PTGS1—malignant glioma	0.000569	0.00115	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—TERT—malignant glioma	0.000553	0.00112	CbGpPWpGaD
Rivaroxaban—CYP3A4—Tryptophan metabolism—CAT—malignant glioma	0.000547	0.0011	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—IDH2—malignant glioma	0.000546	0.0011	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—HIF1A—malignant glioma	0.000529	0.00107	CbGpPWpGaD
Rivaroxaban—CYP2J2—medulla oblongata—malignant glioma	0.000525	0.0903	CbGeAlD
Rivaroxaban—ABCB1—Allograft Rejection—PDGFRA—malignant glioma	0.000521	0.00105	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-B—malignant glioma	0.000517	0.00104	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	0.000515	0.00104	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CYP2B6—malignant glioma	0.000514	0.00104	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PLK1—malignant glioma	0.000511	0.00103	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	0.000498	0.001	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—PDGFB—malignant glioma	0.000494	0.000998	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—malignant glioma	0.000484	0.000977	CbGpPWpGaD
Rivaroxaban—CYP2J2—midbrain—malignant glioma	0.00048	0.0825	CbGeAlD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-A—malignant glioma	0.000479	0.000967	CbGpPWpGaD
Rivaroxaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—malignant glioma	0.000471	0.000951	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—IDH1—malignant glioma	0.00047	0.000948	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—CAV1—malignant glioma	0.000469	0.000946	CbGpPWpGaD
Rivaroxaban—CYP2J2—spinal cord—malignant glioma	0.000468	0.0805	CbGeAlD
Rivaroxaban—CYP2J2—Metabolism—SPHK1—malignant glioma	0.000455	0.000918	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—F2—malignant glioma	0.000446	0.0009	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—FN1—malignant glioma	0.000446	0.0009	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CYP2C18—malignant glioma	0.000445	0.000899	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PML—malignant glioma	0.000432	0.000871	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—PIK3CG—malignant glioma	0.000427	0.000862	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—RTEL1—malignant glioma	0.000425	0.000859	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—EGF—malignant glioma	0.000422	0.000852	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—GSTP1—malignant glioma	0.000421	0.000849	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	0.00042	0.000848	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—PTPN11—malignant glioma	0.000419	0.000846	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—GSTP1—malignant glioma	0.000415	0.000838	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CD80—malignant glioma	0.000404	0.000816	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP2B6—malignant glioma	0.000402	0.000812	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP2B6—malignant glioma	0.000397	0.000801	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TOP2A—malignant glioma	0.000395	0.000797	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—COX8A—malignant glioma	0.000394	0.000795	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—AKT2—malignant glioma	0.000391	0.000788	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	0.000383	0.000772	CbGpPWpGaD
Rivaroxaban—CYP2J2—central nervous system—malignant glioma	0.00038	0.0653	CbGeAlD
Rivaroxaban—F10—Hemostasis—PIK3CD—malignant glioma	0.000375	0.000757	CbGpPWpGaD
Rivaroxaban—CYP2J2—cerebellum—malignant glioma	0.000371	0.0638	CbGeAlD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	0.000369	0.000745	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTT1—malignant glioma	0.00036	0.000727	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—FTH1—malignant glioma	0.00036	0.000727	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—F2—malignant glioma	0.000351	0.000708	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP2C18—malignant glioma	0.000349	0.000704	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP2C18—malignant glioma	0.000344	0.000695	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTGS1—malignant glioma	0.000338	0.000681	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	0.000336	0.000679	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—RAF1—malignant glioma	0.000335	0.000676	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—PIK3CB—malignant glioma	0.000327	0.00066	CbGpPWpGaD
Rivaroxaban—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—malignant glioma	0.000326	0.000657	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—RTEL1—malignant glioma	0.000321	0.000648	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IFNG—malignant glioma	0.00032	0.000645	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ATP1B2—malignant glioma	0.000315	0.000635	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—BCHE—malignant glioma	0.000314	0.000633	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—SLC5A5—malignant glioma	0.00031	0.000626	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—malignant glioma	0.000307	0.00062	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—APOD—malignant glioma	0.000306	0.000618	CbGpPWpGaD
Rivaroxaban—CYP3A4—Tryptophan metabolism—MDM2—malignant glioma	0.000302	0.00061	CbGpPWpGaD
Rivaroxaban—CYP2J2—brain—malignant glioma	0.000301	0.0518	CbGeAlD
Rivaroxaban—F10—Hemostasis—IL2—malignant glioma	0.0003	0.000606	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—MMP2—malignant glioma	0.000298	0.000601	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CXCL8—malignant glioma	0.000297	0.0006	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	0.000293	0.000592	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	0.00029	0.000586	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—malignant glioma	0.000285	0.000576	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IL1B—malignant glioma	0.000285	0.000576	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CASP3—malignant glioma	0.000285	0.000574	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IL2—malignant glioma	0.000284	0.000574	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—malignant glioma	0.000283	0.000571	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GSTT1—malignant glioma	0.000282	0.00057	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—VEGFA—malignant glioma	0.000279	0.000563	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—PTGS1—malignant glioma	0.000264	0.000534	CbGpPWpGaD
Rivaroxaban—ABCB1—blood vessel—malignant glioma	0.000257	0.0443	CbGeAlD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—malignant glioma	0.000257	0.000519	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—VEGFA—malignant glioma	0.000255	0.000515	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	0.000253	0.000511	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTP1—malignant glioma	0.00025	0.000504	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—CXCL8—malignant glioma	0.000247	0.000499	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—COX8A—malignant glioma	0.000244	0.000493	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CAT—malignant glioma	0.000243	0.00049	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—VEGFA—malignant glioma	0.000241	0.000487	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—FGFR1—malignant glioma	0.00023	0.000463	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—NCOR1—malignant glioma	0.000229	0.000463	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—KRAS—malignant glioma	0.000217	0.000438	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ASMT—malignant glioma	0.000208	0.000419	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—TNF—malignant glioma	0.000207	0.000418	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—malignant glioma	0.000206	0.000415	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—PIK3CA—malignant glioma	0.000199	0.000402	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—APC—malignant glioma	0.000199	0.000402	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—RTEL1—malignant glioma	0.000198	0.000399	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—malignant glioma	0.000197	0.000398	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GSTP1—malignant glioma	0.000196	0.000395	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—BCAN—malignant glioma	0.000195	0.000394	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GSTP1—malignant glioma	0.000193	0.000389	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TP53—malignant glioma	0.000193	0.000389	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CAV1—malignant glioma	0.000187	0.000378	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—COX8A—malignant glioma	0.000184	0.000372	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	0.000179	0.000361	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—AKT1—malignant glioma	0.000178	0.000359	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PIK3CG—malignant glioma	0.00017	0.000344	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—malignant glioma	0.000168	0.000339	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PPARG—malignant glioma	0.000164	0.000332	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—AKT1—malignant glioma	0.000163	0.000329	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—malignant glioma	0.000159	0.000321	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—IDH2—malignant glioma	0.000157	0.000318	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—malignant glioma	0.000157	0.000317	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ASMT—malignant glioma	0.000157	0.000316	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—TFRC—malignant glioma	0.000157	0.000316	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—malignant glioma	0.000156	0.000316	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—malignant glioma	0.000155	0.000312	CbGpPWpGaD
Rivaroxaban—ABCB1—embryo—malignant glioma	0.000154	0.0264	CbGeAlD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—malignant glioma	0.000151	0.000305	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PIK3CD—malignant glioma	0.00015	0.000302	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP2B6—malignant glioma	0.000148	0.000299	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—BCAN—malignant glioma	0.000147	0.000298	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—SLC5A5—malignant glioma	0.000144	0.000291	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—malignant glioma	0.00014	0.000283	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—SLC6A3—malignant glioma	0.000137	0.000277	CbGpPWpGaD
Rivaroxaban—ABCB1—retina—malignant glioma	0.000136	0.0234	CbGeAlD
Rivaroxaban—CYP3A5—Metabolism—IDH1—malignant glioma	0.000135	0.000273	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—malignant glioma	0.000132	0.000266	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SPHK1—malignant glioma	0.000131	0.000264	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PIK3CB—malignant glioma	0.000131	0.000264	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTGS2—malignant glioma	0.000129	0.000261	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP2C18—malignant glioma	0.000128	0.000259	CbGpPWpGaD
Rivaroxaban—ABCB1—telencephalon—malignant glioma	0.000125	0.0215	CbGeAlD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—malignant glioma	0.000119	0.000241	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—IDH2—malignant glioma	0.000119	0.00024	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—COX8A—malignant glioma	0.000114	0.000229	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTEN—malignant glioma	0.000113	0.000228	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP2B6—malignant glioma	0.000112	0.000226	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—malignant glioma	0.00011	0.000221	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—malignant glioma	0.000107	0.000216	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTT1—malignant glioma	0.000104	0.00021	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—IDH1—malignant glioma	0.000102	0.000206	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	0.000102	0.000206	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	0.000101	0.000204	CbGpPWpGaD
Rivaroxaban—CYP3A4—central nervous system—malignant glioma	0.0001	0.0172	CbGeAlD
Rivaroxaban—ABCB1—Metabolism—SPHK1—malignant glioma	9.89e-05	0.0002	CbGpPWpGaD
Rivaroxaban—ABCB1—medulla oblongata—malignant glioma	9.81e-05	0.0169	CbGeAlD
Rivaroxaban—CYP3A5—Metabolism—PTGS1—malignant glioma	9.73e-05	0.000196	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP2C18—malignant glioma	9.69e-05	0.000196	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ASMT—malignant glioma	9.66e-05	0.000195	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	9.31e-05	0.000188	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—BCAN—malignant glioma	9.08e-05	0.000183	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—BCHE—malignant glioma	9.04e-05	0.000183	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	9e-05	0.000182	CbGpPWpGaD
Rivaroxaban—ABCB1—midbrain—malignant glioma	8.97e-05	0.0154	CbGeAlD
Rivaroxaban—CYP3A5—Metabolism—SLC5A5—malignant glioma	8.93e-05	0.00018	CbGpPWpGaD
Rivaroxaban—ABCB1—spinal cord—malignant glioma	8.75e-05	0.0151	CbGeAlD
Rivaroxaban—CYP2J2—Metabolism—PIK3CA—malignant glioma	7.96e-05	0.000161	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTT1—malignant glioma	7.83e-05	0.000158	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	7.6e-05	0.000153	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTGS1—malignant glioma	7.34e-05	0.000148	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—IDH2—malignant glioma	7.32e-05	0.000148	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTP1—malignant glioma	7.2e-05	0.000145	CbGpPWpGaD
Rivaroxaban—ABCB1—central nervous system—malignant glioma	7.1e-05	0.0122	CbGeAlD
Rivaroxaban—CYP3A5—Metabolism—CAT—malignant glioma	7e-05	0.000141	CbGpPWpGaD
Rivaroxaban—ABCB1—cerebellum—malignant glioma	6.94e-05	0.0119	CbGeAlD
Rivaroxaban—CYP3A4—Metabolism—CYP2B6—malignant glioma	6.88e-05	0.000139	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—BCHE—malignant glioma	6.82e-05	0.000138	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SLC5A5—malignant glioma	6.74e-05	0.000136	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NCOR1—malignant glioma	6.61e-05	0.000133	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—AKT1—malignant glioma	6.5e-05	0.000131	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—IDH1—malignant glioma	6.3e-05	0.000127	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—RAF1—malignant glioma	6.21e-05	0.000125	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SPHK1—malignant glioma	6.09e-05	0.000123	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP2C18—malignant glioma	5.97e-05	0.00012	CbGpPWpGaD
Rivaroxaban—ABCB1—brain—malignant glioma	5.64e-05	0.00969	CbGeAlD
Rivaroxaban—ABCB1—Metabolism—GSTP1—malignant glioma	5.43e-05	0.00011	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CAV1—malignant glioma	5.39e-05	0.000109	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CAT—malignant glioma	5.28e-05	0.000107	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NCOR1—malignant glioma	4.99e-05	0.000101	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3CG—malignant glioma	4.91e-05	9.91e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTT1—malignant glioma	4.83e-05	9.74e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PPARG—malignant glioma	4.74e-05	9.57e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTGS1—malignant glioma	4.52e-05	9.13e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3CD—malignant glioma	4.32e-05	8.71e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—BCHE—malignant glioma	4.2e-05	8.49e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SLC5A5—malignant glioma	4.15e-05	8.38e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CAV1—malignant glioma	4.07e-05	8.21e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3CB—malignant glioma	3.76e-05	7.59e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTGS2—malignant glioma	3.73e-05	7.53e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3CG—malignant glioma	3.71e-05	7.48e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PPARG—malignant glioma	3.58e-05	7.22e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTP1—malignant glioma	3.35e-05	6.75e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3CD—malignant glioma	3.26e-05	6.58e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CAT—malignant glioma	3.26e-05	6.57e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTEN—malignant glioma	3.25e-05	6.56e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NCOR1—malignant glioma	3.07e-05	6.21e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3CB—malignant glioma	2.84e-05	5.73e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTGS2—malignant glioma	2.81e-05	5.68e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CAV1—malignant glioma	2.51e-05	5.06e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTEN—malignant glioma	2.45e-05	4.95e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3CA—malignant glioma	2.29e-05	4.63e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3CG—malignant glioma	2.28e-05	4.61e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PPARG—malignant glioma	2.2e-05	4.45e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3CD—malignant glioma	2.01e-05	4.05e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—AKT1—malignant glioma	1.87e-05	3.78e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3CB—malignant glioma	1.75e-05	3.53e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTGS2—malignant glioma	1.73e-05	3.5e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3CA—malignant glioma	1.73e-05	3.49e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTEN—malignant glioma	1.51e-05	3.05e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—AKT1—malignant glioma	1.41e-05	2.85e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.07e-05	2.15e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—AKT1—malignant glioma	8.71e-06	1.76e-05	CbGpPWpGaD
